| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3198414 | Journal of Allergy and Clinical Immunology | 2012 | 15 Pages |
Abstract
In this population budesonide/formoterol pMDI was well tolerated over 12 months, with a safety profile similar to that of budesonide; the asthma exacerbation rate was reduced by 38.5% versus budesonide.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Randall W. MD, MPH, Christopher D. MD, PhD, Ubaldo J. MD, Tom MS, Kathy L. MD,